Dashboard
Manage Tickers

IMTXImmatics N.V.

Nasdaq immatics.com


$ 10.88 $ 0.07 (0.65 %)    

Thursday, 02-May-2024 15:59:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 429.07 $ 3.83 (0.9 %)
DIA $ 382.31 $ 3.42 (0.9 %)
SPY $ 505.01 $ 0.61 (0.12 %)
TLT $ 88.87 $ 0.31 (0.35 %)
GLD $ 213.12 $ -0.67 (-0.31 %)
$ 10.89
$ 10.74
$ 0.00 x 0
$ 0.00 x 0
$ 10.74 - $ 10.98
$ 7.15 - $ 13.16
643,761
na
915.15M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
03/21/2024 13:05:49

immatics-q4-gaap-eps-120-down-from-055-yoy-revenue-from-collaboration-agreements-5400m-down-from-17283m-yoy-cash-and-cash-equivalents-and-other-financial-assets-of-4259m-4706m-expected-to-provide-cash-runway-into-2027
Immatics Q4 GAAP EPS €(1.20) Down From €0....
03/21/2024 11:27:50

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
03/18/2024 17:35:23

immatics-prices-175m-public-offering-of-15925000-ordinary-shares-at-11share
Immatics Prices $175M Public Offering Of 1...
01/18/2024 07:05:03

he gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be appro...

immatics-reports-commencement-of-public-offering-of-its-ordinary-shares-no-terms-disclosed
Immatics Reports Commencement Of Public Of...
01/17/2024 21:02:07

immatics-reports-interim-clinical-data-from-actengine-ima203-and-ima203cd8-tcr-t-monotherapies-targeting-prame-in-an-ongoing-phase-1-trial
Immatics Reports Interim Clinical Data Fro...
11/08/2023 12:18:46

cantor-fitzgerald-initiates-coverage-on-immatics-with-overweight-rating
Cantor Fitzgerald Initiates Coverage On Im...
11/02/2023 13:00:00

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Immatics (NASDAQ:IMTX) with a Overweight rating.

immatics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-actengine-ima203-tcr-t-monotherapy
Immatics Receives FDA Regenerative Medicin...
10/24/2023 11:05:56

Core News & Articles
Moderna and Immatics Announce Strategic Mu...
09/11/2023 10:40:37

Moderna, Inc. (NASDAQ:MRNA, &ldquo, Moderna&rdquo, )) and Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, )...

immatics-q2-eps-035-misses-024-estimate-sales-2436m-beat-1893m-estimate
Immatics Q2 EPS $(0.35) Misses $(0.24) Est...
08/17/2023 11:06:44

Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.24) by...

immatics-has-initiated-phase-12-trial-with-its-proprietary-bispecific-t-cell-engaging-receptor-ima402-in-patients-with-advanced-solid-tumors-first-clinical-data-expected-in-2024
Immatics Has Initiated Phase 1/2 Trial Wit...
08/10/2023 11:31:41

why-immatics-shares-are-rising-today
Why Immatics Shares Are Rising Today
07/24/2023 14:05:16

Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced 

Core News & Articles
Bristol Myers Squibb Has Made A $35 Millio...
07/24/2023 11:09:37

immatics-biotechnologies-granted-us-patent-11685769-peptides-for-use-in-immunotherapy-against-cancers
Immatics Biotechnologies Granted U.S. Pate...
06/27/2023 09:39:43

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11685769

top-5-health-care-stocks-that-may-crash-this-month
Top 5 Health Care Stocks That May Crash Th...
06/22/2023 11:32:42

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

immatics-biotechnologies-granted-us-patent-11673917--peptides-combination-of-peptides-and-cell-based-medicaments-for-use-in-immunotherapy-against-urinary-bladder-cancer-and-other-cancers
Immatics Biotechnologies Granted U.S. Pate...
06/13/2023 09:39:19

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11673917

recap-immatics-q1-earnings
Recap: Immatics Q1 Earnings
05/16/2023 13:25:09

immatics-biotechnologies--granted-us-patent-11648276--immunotherapy-against-neuronal-and-brain-tumors-11648292--immunotherapy-against-several-tumors-including-gastrointestinal-and-gastric-cancer
Immatics Biotechnologies Granted U.S. Pat...
05/16/2023 11:40:16

 US 11648276 B2    Abstract The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic m...

immatics-cash-position-of-3298m-with-cash-runway-into-2025
Immatics' Cash Position Of €329.8M, With C...
05/16/2023 11:19:56

immatics-q1-eps-028-beats-030-estimate-sales-1051m-miss-1329m-estimate
Immatics Q1 EPS $(0.28) Beats $(0.30) Esti...
05/16/2023 11:18:41

Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION